Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H28N2O3.ClH |
| Molecular Weight | 368.898 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1=C(O)C(C)=C2CC[C@](C)(OC2=C1C)C(=O)N[C@@H]3CCCNC3
InChI
InChIKey=HVFWCHDZDIRYBZ-MQZJHDQISA-N
InChI=1S/C19H28N2O3.ClH/c1-11-12(2)17-15(13(3)16(11)22)7-8-19(4,24-17)18(23)21-14-6-5-9-20-10-14;/h14,20,22H,5-10H2,1-4H3,(H,21,23);1H/t14-,19+;/m1./s1
| Molecular Formula | C19H28N2O3 |
| Molecular Weight | 332.4372 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
KH-176 is a drug candidate developed by pharmaceutical company Khondrion to treat a range of mitochondrial diseases including MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders. KH176 has been granted Orphan Drug Designation for MELAS spectrum disorders and Leigh disease in Europe and for all inherited mitochondrial respiratory chain disorders in the USA. KH176 acts as a potent intracellular redox-modulating agent essential for the control of oxidative and redox pathologies.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:44:43 GMT 2023
by
admin
on
Sat Dec 16 08:44:43 GMT 2023
|
| Record UNII |
858M8246UL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/15/1543
Created by
admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023
|
||
|
FDA ORPHAN DRUG |
450714
Created by
admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
EU/3/14/1336(POSITIVE)
Created by
admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023
|
PRIMARY | On 15 October 2014, orphan designation (EU/3/14/1336) was granted by the European Commission to Khondrion BV, the Netherlands, for (S)-6-Hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3‑yl)chroman-2-carboxamide hydrochloride for the treatment of Leigh syndrome. | ||
|
EU/3/15/1543(POSITIVE)
Created by
admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023
|
PRIMARY | On 10 August 2015, orphan designation (EU/3/15/1543) was granted by the European Commission to Khondrion BV, the Netherlands, for (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. | ||
|
858M8246UL
Created by
admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023
|
PRIMARY | |||
|
100000180594
Created by
admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023
|
PRIMARY | |||
|
72710874
Created by
admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |